Clinical Trials Sponsored by Shanghai Bio-heart Biological Technology Co., Ltd.

Total 32 results

Shanghai Bio-heart Biological Technology Co., Ltd.

Unknown

Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study

Heart Diseases
Shanghai Bio-heart Biological Technology Co., Ltd.
CCRF Inc., Beijing, China

Active, not recruiting

Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

Coronary Artery Disease | Antineoplastic Agents

China
Shanghai Bio-heart Biological Technology Co., Ltd.
CCRF Inc., Beijing, China

Not yet recruiting

A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

Coronary Artery Disease

China
Shanghai Yiteng Jingang Bio-pharmaceutical Technology...

Recruiting

A Study of EOC237 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Shanghai Unicar-Therapy Bio-medicine Technology...

Recruiting

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

China
Shanghai Unicar-Therapy Bio-medicine Technology...

Recruiting

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Relapsed or Refractory Non-Hodgkin's Lymphoma

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Ruijin Hospital
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Lymphoma

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

Hypercalcemia of Malignancy
Shanghai Unicar-Therapy Bio-medicine Technology...
Shanghai 10th People's Hospital

Recruiting

U87 CART in Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations

China
Shanghai Public Health Clinical Center
Fudan University; Shanghai Xinhao Biological Technology Co., Ltd.

Unknown

Euphorbia Kansui and HIV/AIDS Functional Cure

HIV-1-infection

China
Children's Hospital of Fudan University
Adfontes (Shanghai) Bio-technology Co.,Ltd.

Recruiting

Intervention for Children With Type 1 Diabetes Targeting Gut Microbes (TRIM1)

Type 1 Diabetes

China
Shenzhen Beike Bio-Technology Co., Ltd.
No.85 Hospital, Changning, Shanghai, China

Completed

Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis

Liver Cirrhosis

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer

Prostate Cancer

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

Acute Lymphoblastic Leukemia in Remission

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Acute Lymphoblastic Leukemia With Failed Remission

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

Anti-BCMA CAR T-Cell Therapy for R/R ITP

ITP

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

B-cell Acute Lymphocytic Leukemia

China
First Affiliated Hospital of Harbin Medical University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.

Pancreatic Cancer | CAR

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

Leukemia, B-cell

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Relapse | CD19 Positive | Refractory

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

CAR-T for R/R B-NHL

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | CAR - T CD19/CD20/CD22/CD30

China
Renmin Hospital of Wuhan University
Beijing SH Bio-Tech Corporation, Beijing (CN); Utooth Biological Technology...

Recruiting

Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients

COVID-19

China
Shanghai Unicar-Therapy Bio-medicine Technology...
Peking University People's Hospital; The First Affiliated Hospital of Soochow...

Not yet recruiting

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Platelet Transfusion Refractoriness | Acute Leukemia in Remission

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; Jiangsu Province... and other collaborators

Recruiting

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Multiple Myeloma

China

Clinical Trials Sponsored by Shanghai Bio-heart Biological Technology Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations